124 related articles for article (PubMed ID: 26301881)
41. Serum levels of VEGF-C, VEGF-D, and sVEGF-R2 in patients with lung cancer during chemotherapy.
Naumnik W; Izycki T; Swidzińska E; Ossolińiska M; Chyczewska E
Oncol Res; 2007; 16(9):445-51. PubMed ID: 18074680
[TBL] [Abstract][Full Text] [Related]
42. Elevated serum levels of interleukin-8 in advanced non-small cell lung cancer patients: relationship with prognosis.
Orditura M; De Vita F; Catalano G; Infusino S; Lieto E; Martinelli E; Morgillo F; Castellano P; Pignatelli C; Galizia G
J Interferon Cytokine Res; 2002 Nov; 22(11):1129-35. PubMed ID: 12513912
[TBL] [Abstract][Full Text] [Related]
43. Decreased tumstatin-mRNA is associated with poor outcome in patients with NSCLC.
Luo YQ; Ming Z; Zhao L; Yao LJ; Dong H; Du JP; Wu SZ; Hu W
IUBMB Life; 2012 May; 64(5):423-31. PubMed ID: 22473740
[TBL] [Abstract][Full Text] [Related]
44. [Plasma level and prognostic significance of VEGF, bFGF and MMP-9 in patients with advanced non-small-cell lung cancer].
Zhao J; Liu XY; Zhang QY; Jiang W
Zhonghua Zhong Liu Za Zhi; 2005 Nov; 27(11):676-9. PubMed ID: 16438890
[TBL] [Abstract][Full Text] [Related]
45. Total cyclooxygenase-2 mRNA levels correlate with vascular endothelial growth factor mRNA levels, tumor angiogenesis and prognosis in non-small cell lung cancer patients.
Yuan A; Yu CJ; Shun CT; Luh KT; Kuo SH; Lee YC; Yang PC
Int J Cancer; 2005 Jul; 115(4):545-55. PubMed ID: 15704107
[TBL] [Abstract][Full Text] [Related]
46. Vascular endothelial growth factor A and vascular endothelial growth factor receptor 2 expression in non-small cell lung cancer patients: relation to prognosis.
Bonnesen B; Pappot H; Holmstav J; Skov BG
Lung Cancer; 2009 Dec; 66(3):314-8. PubMed ID: 19324448
[TBL] [Abstract][Full Text] [Related]
47. Levels of vascular endothelial growth factor in serum and pleural fluid are independent predictors of survival in advanced non-small cell lung cancer: results of a prospective study.
Gkiozos I; Tsagouli S; Charpidou A; Grapsa D; Kainis E; Gratziou C; Syrigos K
Anticancer Res; 2015 Feb; 35(2):1129-37. PubMed ID: 25667503
[TBL] [Abstract][Full Text] [Related]
48. Prognostic value of circulating chromogranin A and soluble tumor necrosis factor receptors in advanced nonsmall cell lung cancer.
Gregorc V; Spreafico A; Floriani I; Colombo B; Ludovini V; Pistola L; Bellezza G; Viganò MG; Villa E; Corti A
Cancer; 2007 Aug; 110(4):845-53. PubMed ID: 17599769
[TBL] [Abstract][Full Text] [Related]
49. Angiogenetic biomarkers in non-small cell lung cancer with malignant pleural effusion: correlations with patient survival and pleural effusion control.
Hsu IL; Su WC; Yan JJ; Chang JM; Lai WW
Lung Cancer; 2009 Sep; 65(3):371-6. PubMed ID: 19157636
[TBL] [Abstract][Full Text] [Related]
50. Pretreatment vascular endothelial growth factor (VEGF) and matrix metalloproteinase-9 (MMP-9) serum levels in patients with metastatic non-small cell lung cancer (NSCLC).
Laack E; Scheffler A; Burkholder I; Boeters I; Andritzky B; Schuch G; Görn M; Vohwinkel G; Edler L; Fiedler W; Hossfeld DK
Lung Cancer; 2005 Oct; 50(1):51-8. PubMed ID: 15992959
[TBL] [Abstract][Full Text] [Related]
51. Serum levels of angiopoietin-1, angiopoietin-2, and their receptor tie-2 in patients with nonsmall cell lung cancer during chemotherapy.
Naumnik W; Chyczewska E; Ossolinska M
Cancer Invest; 2009 Aug; 27(7):741-6. PubMed ID: 19340656
[TBL] [Abstract][Full Text] [Related]
52. Expression of pigment epithelial derived factor is reduced in non-small cell lung cancer and is linked to clinical outcome.
Zhang L; Chen J; Ke Y; Mansel RE; Jiang WG
Int J Mol Med; 2006 May; 17(5):937-44. PubMed ID: 16596284
[TBL] [Abstract][Full Text] [Related]
53. [Vascular endothelial growth factor promotes hematogenous metastasis of cancer cells in patients with non-small cell lung cancer].
Dong Q; Feng J; Huang J; Bao G; Sha H; Gu W
Zhonghua Zhong Liu Za Zhi; 2002 Mar; 24(2):142-6. PubMed ID: 12015035
[TBL] [Abstract][Full Text] [Related]
54. Prognostic and Predictive Role of Angiogenic Markers in Non- Small Cell Lung Cancer.
Keskin S; Kutluk AC; Tas F
Asian Pac J Cancer Prev; 2019 Mar; 20(3):733-736. PubMed ID: 30909672
[TBL] [Abstract][Full Text] [Related]
55. Serum interleukin-10 levels as a prognostic factor in advanced non-small cell lung cancer patients.
De Vita F; Orditura M; Galizia G; Romano C; Roscigno A; Lieto E; Catalano G
Chest; 2000 Feb; 117(2):365-73. PubMed ID: 10669676
[TBL] [Abstract][Full Text] [Related]
56. Fibroblast Growth Factor Receptor 1 (FGFR1), Partly Related to Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) and Microvessel Density, is an Independent Prognostic Factor for Non-Small Cell Lung Cancer.
Pu D; Liu J; Li Z; Zhu J; Hou M
Med Sci Monit; 2017 Jan; 23():247-257. PubMed ID: 28088809
[TBL] [Abstract][Full Text] [Related]
57. Serum levels of the cancer-testis antigen POTEE and its clinical significance in non-small-cell lung cancer.
Wang Q; Li X; Ren S; Cheng N; Zhao M; Zhang Y; Li J; Cai W; Zhao C; Cao W; Zhou C
PLoS One; 2015; 10(4):e0122792. PubMed ID: 25860145
[TBL] [Abstract][Full Text] [Related]
58. Inflammatory cytokines and VEGF measured in exhaled breath condensate are correlated with tumor mass in non-small cell lung cancer.
Brussino L; Culla B; Bucca C; Giobbe R; Boita M; Isaia G; Heffler E; Oliaro A; Filosso P; Rolla G
J Breath Res; 2014 Jun; 8(2):027110. PubMed ID: 24861949
[TBL] [Abstract][Full Text] [Related]
59. Serum cripto-1 as a clinical marker for lung cancer.
Xu CH; Cao L; Wei Y; Yu LK
Int J Biol Markers; 2015 Nov; 30(4):e369-73. PubMed ID: 26109366
[TBL] [Abstract][Full Text] [Related]
60. Platelet VEGF and serum TGF-β1 levels predict chemotherapy response in non-small cell lung cancer patients.
Fu BH; Fu ZZ; Meng W; Gu T; Sun XD; Zhang Z
Tumour Biol; 2015 Aug; 36(8):6477-83. PubMed ID: 25820820
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
